83217-48-5

Upstream product

• 83217-44-1 4,6-dichloro-2-(4-methylsulfanylphenyl)pyrimidine 

Downstream Products

• 1018481-37-2 4-chloro-6-ethoxy-2-(4- (methylsulfonyl)phenyl)pyrimidine 
• 1018481-38-3 4-chloro-2-(4-methanesulfonylphenyl)-6-(2-methoxyethoxy)pyrimidine 
• 1018481-39-4 4-chloro-6-cyclopentyloxy-2-(4-methanesulfonylphenyl)pyrimidine 
• 1018481-14-5 C₁₈H₁₅ClFN₃O₂S 
• 1018480-90-4 N-benzyl-6-chloro-2-(4-(methylsulfonyl)phenyl)pyrimidin-4-amine 
• 1018481-10-1 C₁₉H₁₈ClN₃O₂S 
• 1018481-40-7 4-chloro-6-(ethylthio)-2- (4(methylsulfonyl)phenyl)pyrimidine 
• 1018480-97-1 C₁₆H₁₅N₃O₃S₂ 
• 1018480-93-7 C₁₈H₁₉N₃O₂S₃ 
• 1018481-36-1 4-chloro-2-(4-methanesulfonylphenyl)-6-methoxypyrimidine 
• 1018480-91-5 6-chloro-2-(4-(methylsulfonyl)phenyl)-N-(thiophen-2-ylmethyl)pyrimidin-4-amine 

Relevant academic research and scientific papers

Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors

New series of 2-(4-methylsulfonylphenyl) and 2-(4-sulfamoylphenyl)pyrimidines were synthesized and evaluated for their ability to inhibit cyclooxygenase-2 (COX-2). COX-1 and COX-2 inhibitory activity of these compounds was determined using purified enzyme (PE) and human whole blood (HWB) assays. Extensive structure-activity relationship (SAR) work was carried out within these series, and a wide number of potent and specific COX-2 inhibitors were identified (HWB COX-2 IC50 = 2.4-0.3 nM and 80- to 780-fold more selective than rofecoxib).